Enzymes in the cholesterol pathway have emerged as effective drug targets for the prevention and treatment of Alzheimer's disease (AD). Although statins reduced beta-amyloid (A?) in cells and animal models, so far yielded disappointing results in phase III clinical trials for AD. A cholesterol-modifying enzyme named acyl-coenzyme A: cholesterol acyltransferase (ACAT) is becoming an exciting target for AD therapy and atherosclerosis. All three classes of existing ACAT inhibitors, knockdown of ACAT in cells and in AD mouse models reduce A? production. We have recently made considerable progress toward understanding the mechanism by which ACAT inhibition decreases A? levels. Specifically, we have found that the amyloid precursor protein (APP) is modified by the addition of a fatty acid in a process called palmitoylation. We were able to show that palmitoylation of APP is highly regulated by ACAT activity. In addition, we have identified a series of novel ACAT inhibitors. The overarching goal of this application is to elucidate the precise mechanism of action and therapeutic efficacy of ACAT inhibitors in AD, with particular focus on our novel compounds. To this end, we propose to use an integrated approach of cell biology and in vivo animal models. We will identify the palmitoylating enzyme of APP and ask whether ACAT inhibitors affect its expression or localization. We will also study how palmitoylated APP gives rise to A? and how ACAT inhibitors specifically reduce this process. Lastly, we will test the therapeutic potential of our novel ACAT inhibitors in animal models of AD and how ACAT inhibition regulates palmitoylated APP in vivo. Collectively, the goal of these experiments is to provide the necessary mechanistic and in vivo data for further development of ACAT inhibitors as a therapeutic strategy for AD and perhaps cardiovascular disease.

Public Health Relevance

Cholesterol-based Ab-lowering agents are emerging as attractive therapeutic strategies for AD. This proposal directly tests the mechanism of established and novel ACAT inhibitors in reducing beta-amyloid levels in neurons and AD animal models. These studies will greatly facilitate the understanding and development of cholesterol-based therapies for the prevention and treatment of Alzheimer's disease and perhaps cardiovascular disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS045860-11
Application #
8295228
Study Section
Cell Death in Neurodegeneration Study Section (CDIN)
Program Officer
Corriveau, Roderick A
Project Start
2002-09-23
Project End
2017-03-31
Budget Start
2012-06-15
Budget End
2013-03-31
Support Year
11
Fiscal Year
2012
Total Cost
$369,647
Indirect Cost
$150,897
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Gautam, Vivek; D'Avanzo, Carla; Hebisch, Matthias et al. (2014) BACE1 activity regulates cell surface contactin-2 levels. Mol Neurodegener 9:4
Kim, Doo Yeon; Wertz, Mary H; Gautam, Vivek et al. (2014) The E280A presenilin mutation reduces voltage-gated sodium channel levels in neuronal cells. Neurodegener Dis 13:64-8
Bhattacharyya, Raja; Barren, Cory; Kovacs, Dora M (2013) Palmitoylation of amyloid precursor protein regulates amyloidogenic processing in lipid rafts. J Neurosci 33:11169-83
Huttunen, Henri J; Havas, Daniel; Peach, Camilla et al. (2010) The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. J Neuropathol Exp Neurol 69:777-88
Bhattacharyya, Raja; Kovacs, Dora M (2010) ACAT inhibition and amyloid beta reduction. Biochim Biophys Acta 1801:960-5
Huttunen, Henri J; Peach, Camilla; Bhattacharyya, Raja et al. (2009) Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J 23:3819-28
Huttunen, Henri J; Puglielli, Luigi; Ellis, Blake C et al. (2009) Novel N-terminal cleavage of APP precludes Abeta generation in ACAT-defective AC29 cells. J Mol Neurosci 37:6-15
Huttunen, Henri J; Kovacs, Dora M (2008) ACAT as a drug target for Alzheimer's disease. Neurodegener Dis 5:212-4
Huttunen, Henri J; Greco, Christopher; Kovacs, Dora M (2007) Knockdown of ACAT-1 reduces amyloidogenic processing of APP. FEBS Lett 581:1688-92